Application

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected RBPMS in mouse retina, rat heart, and HepG2 cell lysates.Flow Cytometry Analysis: 0.1 µg from a representative lot detected RBPMS in one million A549 cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected RBPMS in human kidney tissue sections.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-RBPMS, clone 1E16 ZooMAb, Cat. No. ZRB1622, is a recombinant Rabbit monoclonal antibody that specifically targets RBPMS and is tested for use in Flow Cytometry, Immunohistochemistry (Paraffin), and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

KLH-conjugated linear peptide corresponding to 21 amino acids from the N-terminal region of human RNA-binding protein with multiple splicing (RBPMS).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

30 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 1E16 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects RNA-binding protein with multiple splicing (RBPMS). It targets an epitope within 21 amino acids from the N-terminal region. May show reactivitry with all isoforms.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

RNA-binding protein with multiple splicing (UniProt: Q93062; also known as RBP-MS, Heart and RRM expressed sequence, Hermes, RBPMS) is encoded by the RBPMS (also known as HERMES) gene (Gene ID: 11030) in human. RBPMS is a ubiquitously expressed homodimeric protein that acts as a coactivator of transcriptional activity. Its expression level varies depending on the isoform and the tissue type. Its each protein chain binds one RNA molecule via the external surface of the homodimer. It is mainly localized in the nucleus, but it translocates into cytoplasmic stress granules that correspond to P-bodies in response to oxidative stress. It contains a RRM domain (aa 24-101) that is required for its interaction with SMAD4. RBPMS is shown to increase TGF1/SMAD-mediated transactivation. It increases phosphorylation of SMAD2 and SMAD3 on their C-terminal SSXS motif and enhances nuclear accumulation of SMAD proteins. RBPMS also controls alternative RNA splicing of many genes that are essential in smooth muscle cells and any disruption in its regulation results in certain diseases of the heart and blood vessels. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Nakagaki-Silva, EE et al., (2019). eLife. 8; 46327).